Pyruvate dehydrogenase E1 component subunit alpha 1 (PDHA1)

Pyruvate dehydrogenase E1 component subunit alpha 1 (PDHA1) is a mitochondrial enzyme and the catalytic alpha subunit of the E1 component within the pyruvate dehydrogenase complex (PDC)[1][3]. This multienzyme complex forms a critical metabolic “gatekeeper,” catalyzing the irreversible conversion of pyruvate to acetyl-CoA, thus linking glycolysis with the tricarboxylic acid (TCA) cycle and cellular respiration[1][3]. The E1 component is a heterotetramer composed of two alpha (PDHA1) and two beta (PDHB) subunits; PDHA1 houses the active site. PDHA1 activity is dynamically regulated by reversible phosphorylation and is also modulated by factors such as insulin and growth signals. Genetic deficiency of PDHA1 impairs mitochondrial energy production and manifests as severe metabolic and neurological disorders. In oncology, PDHA1 dysregulation participates in metabolic reprogramming, contributing to cancer cell survival and proliferation by promoting the Warburg effect[1][2][3]. Recent evidence highlights its utility as a prognostic biomarker and as a potential target for therapeutic intervention, especially in hepatocellular carcinoma, where its expression influences response to various chemotherapies[2].

Other names

Pyruvate dehydrogenase (lipoamide) alpha 1PDHAPDHCE1APHE1APDHADpyruvate dehydrogenase alpha 1pyruvate dehydrogenase E1 alpha 1 subunitpyruvate dehydrogenase E1 subunit alpha 1E1alphaE1-alpha componentpyruvate dehydrogenase complex E1-alpha polypeptide 1

Chemotherapeutic agents modulating or leveraging PDHA1 expression or activity may reprogram tumor metabolism and induce apoptosis in cancer cells. Overexpression or pharmacological activation promotes conversion of pyruvate to acetyl-CoA, inhibiting aerobic glycolysis (Warburg effect) and promoting oxidative phosphorylation, leading to reduced cell proliferation and increased apoptosis.